Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids

Thrombosis and Haemostasis

Volumn 75, Issue 5, 1996, Pages 796-800

  Valentin, Sanne ^a,b   Schousboe, Inger ^b  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CALCIUM; HEPARIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; PRIORITY JOURNAL;

EID: 0029982380     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650369     Document Type: Article

References (22)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
2. Warn-Cramer BJ, Rao LMW, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453-6.
3. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard TJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
4. Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Møller KB, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor: Production, isolation and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265: 16786-93.
5. Callander NS, Rao LVM, Nordfang O, Sandset PM, Warn-Cramer B, Rapaport SI. Mechanisms of binding of recombinant extrinsic pathway inhibitor (EPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J Biol Chem 1992; 267: 876-82.
6. Lindhout T, Willems G, Blezer R, Hemker HC. Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Biochem J 1994; 297: 131-6.
7. Hamamoto T, Yamamoto Y, Nordfang O, Petersen JGL, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated tissue factor pathway inhibitor. J Biol Chem 1993; 268: 8704-10.
8. Valentin S, Reutlingsperger CPM, Nordfang O, Lindhout T. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: A comparison between tissue factor pathway inhibitor and inactive factor VIIa. Thromb Haemost 1995; 74: 1478-85.
9. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitor domains, J Biol Chem 1988; 263: 6001-4.
10. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
11. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ, Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coag Fibrinol 1993; 4: 661-9.
12. Petersen JGL, Meyn G, Rasmussen JS, Christiansen L, Petersen J, Bjørn SE, Jonassen I, Nordfang O, Characterization of human tissue factor pathway inhibitor (TFPI) variants expressed in Saccharomyces cerevisae. J Biol Chem 1993; 268: 13344-51.
13. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
14. Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-7.
15. Novotny WF, Girard TF, Miletich JP, Broze GJ. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein-associated coagulation inhibitor. Blood 1988; 71: 2020-5.
16. Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a "prima ballerina". Thromb Haemost 1995; 74: 7-17.
17. Nordfang O, Bjørn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991; 30: 10371-6.
18. Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding-time in rabbits with antibody-induced hemophilia-A. Blood Coag Fibrinol 1995; 6: 388-94.
19. Schousboe I, Halkier T. Zinc ions promote the binding of factor XII/ factor XIIa to acidic phospholipids but have no effect on the binding of high-Mr kininogen. Eur J Biochem; 1991: 309-14.
20. Bloom JW. The interactions of factors X and IX with phospholipid. Thromb Res 1989; 54: 261-8.
21. Valentin S, Nordfang O, Bregengård C, Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coag Fibrinol 1993; 4: 713-20.
22. Broze GJ, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coag Fibrinol 1994; 5: 551-9.